Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of early deferasirox in transfusion-dependent myelodysplastic syndromes
2011-004559-38Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in iron overload and myelodysplastic syndrome (MDS), sponsored by University of Birmingham. Primary endpoint: Time to mean serum ferritin greater than 1500 micrograms/L. Started Jun 2012; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overloadmyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2011-004559-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004559-38.